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Myelodysplastic syndromes (MDS) are a group of hematologic disorders characterized by ineffective hematopoiesis
that results in reduced blood counts. Although MDS can transform into leukemia, most of the morbidity
experienced by these patients is due to chronically low blood counts. Conventional cytotoxic agents used to treat
MDS have yielded some encouraging results but are characterized by many adverse effects in the predominantly
elderly patient population. Targeted interventions aimed at reversing the bone marrow failure and increasing the
peripheral blood counts would be advantageous in this cohort of patients. Studies have demonstrated
over-activated signaling of myelo-suppressive cytokines such as TGF-β, TNF-α and Interferons in MDS hematopoietic
stem cells. Targeting these signaling cascades could be potentially therapeutic in MDS. The p38 MAP kinase
pathway, which is constitutively activated in MDS, is an example of cytokine stimulated kinase that promotes
aberrant apoptosis of stem and progenitor cells in MDS. ARRY-614 and SCIO-469 are p38 MAPK inhibitors that have
been used in clinical trials and have shown activity in a subset of MDS patients. TGF-β signaling has been
therapeutically targeted by small molecule inhibitor of the TGF-β receptor kinase, LY-2157299, with encouraging
preclinical results. Apart from TGF-β receptor kinase inhibition, members of TGF-β super family and BMP ligands
have also been targeted by ligand trap compounds like Sotatercept (ACE-011) and ACE-536. The multikinase
inhibitor, ON-01910.Na (Rigosertib) has demonstrated early signs of efficacy in reducing the percentage of leukemic
blasts and is in advanced stages of clinical testing. Temsirolimus, Deforolimus and other mTOR inhibitors are being
tested in clinical trials and have shown preclinical efficacy in CMML. EGF receptor inhibitors, Erlotinib and Gefitinib
have shown efficacy in small trials that may be related to off target effects. Cell cycle regulator inhibitors such as
Farnesyl transferase inhibitors (Tipifarnib, Lonafarnib) and MEK inhibitor (GSK1120212) have shown acceptable
toxicity profiles in small studies and efforts are underway to select mutational subgroups of MDS and AML that may
benefit from these inhibitors. Altogether, these studies show that targeting various signal transduction pathways
that regulate hematopoiesis offers promising therapeutic potential in this disease. Future studies in combination
with high resolution correlative studies will clarify the subgroup specific efficacies of these agents.
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Introduction
Myelodysplastic syndromes (MDS) encompass a spectrum
of hematologic diseases characterized by ineffective hema-
topoiesis in the marrow that leads to refractory cytopenia.
Based on the degree of cytopenia and malignant potential,
MDS can be classified as low or high grade subtypes, using
the International Prognostic Scoring System [1]. In low
grade MDS, marrow hyper cellularity and peripheral cy-
topenia are commonly seen due to upregulated apoptosis
in the progenitor stem cells. However decreased apoptosis
is seen during transformation to higher risk MDS, which
often manifests with an increase in myeloblasts [2]. Most
patients present with low risk disease and experience mor-
bidity due to anemia, neutropenia or thrombocytopenia.
Strategies to raise blood counts are needed to alleviate
morbidity in these patients. Despite numerous advances,
better understanding of pathways regulating hematopoiesis
is still lacking. Since cytokines are important in regulating
differentiation of hematopoietic cells, targeting them ap-
pears to be a rational therapeutic strategy in MDS. Various
studies suggest Tumor Necrosis factor α(TNF α) [3],









Figure 1 Regulation of hematopoiesis by cytokines. The process of diff
tightly regulated by the actions of both stimulatory and inhibitory cytokineendothelial Growth Factor (VEGF) [5], Activin receptor
like kinase (ALK) [6], Interleukins(ILs) [7], and Interferons
(IFN) [8] regulate the bone marrow milieu in MDS. The
physiologic effects of a few of these cytokines are executed
by the support of transcription regulators like the JAK-
STAT pathway and many other pathways [9]. Hence
strategies that can balance the effects of the stimulatory
and inhibitory cytokine pathways can potentially be of
therapeutic utility in MDS and other hematologic neo-
plasm [10,11].
Cytokine regulation of hematopoiesis
A complex interplay of various cytokines has been implied
in maintaining normal hematopoiesis. Growth factors
such as erythropoietin (EPO), Granulocyte macrophage
colony stimulating factor (GM-CSF), Granulocyte colony
stimulating factor (G-CSF) and Interleukin-3 promotes
the differentiation of erythroid and myeloid progenitors
[12]. On the other hand, Interferons, Interleukins, TGF-β
and TNF-α have inhibitory actions on hematopoietic stem
cells (Figures 1 and 2). It is conceivable that an imbalance
between the action of inhibitory and stimulatory cytokines
can lead to increased myelo-suppression and boneWTH FACTORS 








erentiation of hematopoietic stem cells into mature blood cells is
s.
Figure 2 Model for pathogenesis of MDS. A mutation or epigenetic alteration in hematopoietic stem cells (HSC), leads to generation of
pro-inflammatory milieu in marrow microenvironment that can result in apoptotic cell death of normal HSCs. Inhibition of myelo-suppressive
cytokine signaling cascades can stimulate hematopoietic activity in HSCs.
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cytokines is seen in MDS, thus making these pathways a
potential target for therapy.
P38 Mitogen Activated Protein (MAP) Kinase -
Therapeutic target in MDS
Various inhibitory cytokines can activate the p38 MAPK
pathway in the hematopoietic progenitor cells (Figure 3).
In prior studies we have shown that this pathway is
constitutively activated in MDS [13-15]. Activation of
p38 MAPK was seen in a large proportion of bone mar-
row cells of patients with low grade MDS, with a greater
number of phospho-p38-positive staining cells and
significantly higher intensity of immunohistochemicalFigure 3 Mitogen activated protein kinases. These are
evolutionarily conserved protein kinases that regulate many
important physiological processes. The p38 MAP kinase regulates
cell death and proliferation in hematopoietic cells.staining when compared to anemic non-MDS controls.
We also determined that p38 MAPK activation mediates
enhanced progenitor cell apoptosis seen in MDS bone
marrows. Thus blocking this pathway is a potential
therapeutic strategy that can lead to decrease in apop-
tosis and enhanced survival of hematopoietic stem and
progenitor cells.
The compound SCIO-469, was the first small molecule
inhibitor of the p38 MAPK that was tested clinically in
MDS [16]. By predominantly inhibiting the alpha iso-
form (dominant isoform in MDS) of the P38 MAPK, this
compound could stimulate hematopoiesis from MDS
progenitors in vitro [17]. A phase 1/ 2 multi center trial
of SCIO- 469 (N-62) was conducted in patients with low
to intermediate risk MDS [18]. Patients in this trial re-
ceived SCIO-469 at doses of 30 mg TID (n-15), 60 mg
TID (n-15) and 90 mg TID (n-15). Due to the fact that
the maximum tolerable dose was not achieved, an ad-
ditional arm with 120 mg TID dosing (n-17) was added
to the trial. Based on International Working Group cri-
teria, responders were evaluated with an intention to
continue using the drug until a maximum of 104 weeks
of therapy. Of the 62 patients enrolled in the study only
47 of them completed the treatment till week 16. Only
12 of these patients were able to continue therapy after
week 16 and 5 of them completed treatment till week
52. About 29% of patients (18 out of 62) experienced HI
in each of the hematopoietic lineage. Amongst 62 study
recruited patients, erythroid (6 major, 5 minor), neutro-
phil (3 major, 3 minor) and platelets (1 major) response
were documented. Five patients were found to have
progression of disease, 36 patients had stable disease and
1 patient achieved a cytogenetic response. Hence it was
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as a monotherapy in low- int risk MDS and recommended
further studies at higher doses.
More recently, another p38 MAPK inhibitor, ARRY-614,
has shown promising activity in MDS. This compound
can block both the p38 MAPK and the Tie-2 pathway.
Tie-2 pathway has been noted to complement P38 MAP
kinase pathway in cytokine regulation and phenotypic
maturation of hematopoietic stem cells [19]. Tie-2 ligands
have been found to be over-expressed in marrows of MDS
patients and higher expression of Tie-2 has been corre-
lated as a poor prognostic indicator [20]. A phase I trial of
Arry-614 in low (n-11)/int-1(n-34) risk, heavily pretreated
cohort of MDS patients was conducted recently [21]. In
the inclusion criterion, prior therapies with erythropoietin
stimulating agents (49%), hypo-methylating agents (82%)
and lenalidomide (40%) were permitted. ARRY- 614 at
doses of 400-1200 mg once daily and 200-300 mg twice
daily was administered in fasting state patients and a dose
of 400 mg daily was tested in non- fasting state. Of the 43
evaluable patients, hematological improvement was noted
in 8 patients (erythroid- 4, platelet-4 and neutrophil-5).
Interestingly 5 bilineage improvement in counts was
reported. Also the study demonstrated that ARRY-614
decreased the baseline elevated EPO levels and reduced
platelet transfusions in patients who had failed therapy
with hypomethylating agents. Hence it was hypothesized
by the authors that addition of recombinant EPO in
combination with ARRY- 614 may further optimize eryth-
roid responses. Correlative studies showed that treatment
with ARRY-614 resulted in an 85% reduction of phospho-
rylated/activated-p38 levels in the marrow along with
concomitant decreased apoptosis [22]. Based on encou-
raging responses, particularly in patients that failed hypo-
methylating agents, further clinical studies are being
planned with this drug.Transforming Growth Factor- β (TGF- β) inhibitors
The role of TGF- β cytokine on inhibition of normal stem
and progenitor cells is well documented [23]. TGF-β binds
to a set of TGF-β receptors and lead to activation of intra-
cellular SMAD 2/3 proteins. These proteins associate with
other cofactors and translocate to the nucleus to mediate
the biological actions on stem cells. We have demonstrated
that smad2, a downstream mediator of TGF-β receptor I
kinase (TBRI) activation, is constitutively activated and
over expressed in MDS bone marrow precursors [24].
Furthermore, we showed that shRNA mediated down
regulation as well as pharmacologic inhibition of TBRI
leads to enhanced hematopoiesis in a variety of MDS sub-
types in vitro. TBRI kinase inhibition also alleviated anemia
and stimulated hematopoiesis in a mouse model of bone
marrow failure, demonstrating it as a potential therapeutictarget in MDS [4]. These studies provided a preclinical
rationale for targeting TGF-β signaling pathways in MDS.
LY2157299 is a novel small molecule that specifically
inhibits the kinase activity of the Transforming Growth
Factor- β Type I Receptor (TGF- β RI) and its down-
stream signaling pathway. In vitro and In vivo studies
have shown the efficacy of LY2157299 in stimulating
hematopoiesis in MDS [25], thus providing the rationale
for using this drug in MDS (Figure 4). This agent is
clinically relevant and has shown adequate safety signals
in phase I studies in solid tumors [26]. This agent is also
being tested clinically in gliomas and will be evaluated in
MDS in the near future.
Activin and TGF-beta receptor ligand traps
The stimulatory role of erythropoietin (EPO) in erythro-
poiesis has been well established [27]. Hematopoietic cells
in MDS are usually resistant to EPO and increased EPO
level, reflecting a refractory state to therapy is often seen
in the long course of this disease [28]. Consequently, only
a minority of patients respond to recombinant EPO [29].
Activin family members belong to the TGF-superfamily
ligands and plays important roles in cellular development
of many different tissues including the hematopoietic
tissue [30]. Hence compounds that can regulate Activin
mediated hematopoietic activity have been tested for cli-
nical applicability in MDS. ACE-536 is a modified type-II
Activin receptor fusion protein and serves as a ligand trap
for TGF- β family members that are involved in erythroid
differentiation. Preclinical trials in C57BL/6 mice were as-
sociated with rise in hematocrit, red blood cells and
hemoglobin parameters at doses of 10 mg/kg. The authors
of this study observed a rapid proliferation of late stages
of erythroid precursors, independent of EPO mediated
mechanisms [31]. The encouraging stimulation of erythro-
poiesis observed led to further tests in the NUP98/HOX
murine model of MDS [32]. When RAP-536 (The murine
homolog of human ACE-536) was injected at 10 mg/kg,
twice a week for 8 months, it led to significant improve-
ments in hematologic parameters in comparison to con-
trol studied. Authors reported that progression of anemia
was much slower in mice treated with RAP-536 (8.3% vs.
22% in HCT and 13% vs. 30% in RBC). Lack of increased
blasts detected probably suggests a reduction in trans-
formation to leukemia with RAP-536 treatment [33]. Cur-
rently a few phase-1/2 studies (Table one) are evaluating
the role of ACE-536 in treating anemia.
Sotatercept (formerly known as ACE- 011) (fusion pro-
tein of Human soluble Activin receptor type-IIA and Fc-
portion of human IgG1) [34] is another ligand trap that
has been shown to inhibit the inhibitory SMAD2/3 signa-
ling in hematopoietic cells [35]. A recent clinical report of
sotatercept in cancer patients and healthy volunteers has
shown a rapid rise in hemoglobin and reticulocyte counts
Figure 4 TGF-β signaling pathway. TGF-β receptors after binding with the TGF-β ligand, forms a receptor- ligand complex. This dimerization
activates the kinase domain of Type I receptor. The activated Type 1 receptor kinase further activates the downstream smad complexes to
regulate gene transcription. LY2157299 inhibits the TGF-β receptor I kinase and can reverse the cellular effects of TGF- β signaling pathway in
hematopoietic cells.
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and NCT01736683) have been initiated and will explore
the efficacy of this agent in treating anemia associated
with marrow failure syndromes.
Multi kinase inhibitor
Onconova-01910.Na (Rigosertib) is a multi-kinase inhibi-
tor of Polo like kinase, Akt and PI3 kinase pathways [37].
It appears to have selectivity for tumor cells containing
these activated pathways and can cause apoptosis by indu-
cing mitotic arrest at G2/M phase of cell cycle [38]. Pre-
clinical studies in MDS demonstrated that ON-01910
could induce selective apoptosis in myeloid cells with tri-
somy of chromosome 8. Trisomy 8 is a frequent cytogen-
etic alteration in MDS and is associated with upregulation
of cyclin D1 and c-myc proteins, which drive cellular pro-
liferation. Treatment of primary MDS samples containing
trisomy 8 with ON-01910 showed a reduction in CD34+
blasts in the first Phase 1 (NCT00533416) study conducted
[39]. The trial included 12 patients with High risk MDS
and 2 AML patients with trisomy-8. As reported in the
study, 3 patients had greater than 50% reduction in blast
counts & 3 patients achieved hematologic improvement as
per IWG criteria. All patients that showed a hematologic
response to ON-01910 had reduced expression of cyclinD1 in CD34+ cells post therapy [39]. A more recent trial
with Rigosertib in 60 MDS patients demonstrated the
ability of this drug in reducing blasts and also revealed a
positive correlation between bone marrow response and
overall survival [40]. The encouraging results offered by
this study have prompted an ongoing phase 3 study in
MDS patients who have failed hypo-methylating agent
therapy.
Mammalian target of rapamycin inhibitors (mTOR
inhibitors)
The PI3K/mTOR pathway is an intracellular signaling path-
way that is well studied in various cancers [41]. PI3K is a
serine/threonine protein kinase that acts as a fulcrum and
interface for various downstream pathways concerned with
cell proliferation and metabolism [42,43]. By controlling
enzymatic activity and decreasing angiogenesis, mTOR in-
hibitors have shown antiproliferative effects in various
malignancies [44]. Preclinical studies have shown the onco-
gene, Ecotropic Viral Integration Site 1(EVI1) [45], a
nuclear transcription factor is necessary for hematopoietic
stem cell proliferation & differentiation. In MDS and mye-
loid malignancies with EVI1 translocations, this transcrip-
tion factor can cause PTEN repression and activation of
PI3K/mTOR pathways [46], thereby leading to increased
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mTOR inhibitors are being studied as a novel strategy in
treating MDS and other hematologic malignancies.
Deforolimus has been studied in relapsed or refractory
hematologic malignancies and has shown antitumor ac-
tivity [47]. Temsirolimus is currently being evaluated in
the TEMDS (Temsirolimus in MDS Study) trial (NCT
01111448). Unfortunately, NCT 00809185 which was
meant to evaluate everolimus in MDS was terminated
due to slow accrual. Despite this initial set back, with
results of many studies yet to be presented, the role of
mTOR inhibition could still hold promise in MDS [48].
Epithelial Growth Factor Receptor (EGFR) inhibitors
The arrival of EGFR inhibitors in clinical practice has
significantly changed the landscape of lung cancer treat-
ment in modern era and a similar attempt to replicate this
success is tried in other cancers [49,50]. An interesting re-
port of Gefitinib induced differentiation in AML cell lines
and AML patient samples [51], spurred preclinical studies
that reported pro apoptotic and anti-mitotic effects of
erlotinib in EGFR negative MDS and AML cell lines [52].
This off target effect of EGFR inhibitor was attributed to
blockage of Jak2/Stat-5 pathway in subsequent experi-
ments [53]. A phase 2 study of erlotinib in MDS was
reported at ASH 2010 [54]. In this study, patients who re-
ceived Tarceva had failed prior Azacytadine or Decitabine.
Amongst 23 reportable study patients who received
150 mg Erlotinib tablets daily for 16 weeks, 3 went into
CR, 1 showed hematologic improvement and 6 had stable
disease. 4 patients died in the study arm. Diarrhea, platelet
disorders and rash were commonly observed adverse
events. Currently there is an ongoing NCT 1085838 cli-
nical trial that is looking further into the role of erlotinib
in High risk MDS. These studies have now been followed
up by preclinical evaluation of combining erlotinib with
azacytadine [55]. Another preclinical study reported that
the combination of erlotinib with chemotherapeutic
agents, leads to increased chemosensitivity in AML cell
lines. This synergistic effect observed was achieved by
promoting apoptosis and inhibiting the drug efflux from
cells via inhibition of the ABC transporters [56]. Based
on these pre clinical studies further clinical studies are
being designed to explore combinations of EGFR inhibi-
tors with other agents.
Ezatiostat (TLK199) (Glutathione S Transferase1-1
inhibitor)
The enzyme GSTP1-1 (GSTP- Glutathione S Transferase
pi1) can bind and inhibit the Jun Kinases with subsequent
impact on growth and differentiation of healthy hema-
topoietic stem cells and cancer cells [57]. Ezatiostat is
structurally analogous to Glutathione and can displace it
from the glutathione binding site needed to inhibit the JunKinase pathways. Hence Ezatiostat acts as a Glutathione
S-Transferase P1-1 inhibitor and activates the pro apop-
totic Jun kinase in cancer cells that express GSTP1-1[58].
This action promotes growth and maturation of normal
hematopoietic progenitors and induces apoptosis in can-
cer cell lines. A recent phase 2 trial of Ezatiostat using 2
dosing schedules for heavily pretreated Low/Int-1 risk
MDS (n-89) led to RBC transfusion reduction in 29% and
independence in 11% of transfusion dependent population
[59]. Liposomal preparation of the compound showed en-
couraging results in one other Phase 2 MDS study [60].
The oral formulation of the compound is currently being
studied in del5q MDS (NCT01422486). Since there are
limited effective therapeutic options in non- del 5q MDS
patients (low and intermediate-1 risk), Ezatiostat has been
explored in combination with Lenalidomide in a phase-1
study. As per the design of this study patients re-
ceived a starting dose of Lenalidomide 10 mg for every
21 days followed by a week break in combination with
2 grams/day Ezatiostat. Dose escalation of Ezatiostat to
2.5 grams/day without changing the dose of Lenalidomide
was carried out to determine the maximal tolerable
dose and to determine the efficacy of combination therapy
measured in terms of hematologic improvement. Amongst
the 2.5 grams/day Ezatiostat with 10 mg Lenalidomide
receiving arm, about 25% of the patients experienced
HI- E response. The HI- E response rate was 40% in
2 grams/day Ezatiostat arm and approximately 43% of
patients who were red blood cell transfusion dependent
prior to therapy become independent of transfusion
post therapy. Also 60% of patients showed HI- P response.
A significant proportion of bilineage (Erythroid/Platelet-
60%) (Erythroid/Neutrophil and Neutrophil/Platelet- 33%)
response was observed in 2000 mg Ezatiostat arm. Inter-
estingly, 33% of patients had trilineage improvement with
this combination. The combination was well tolerated and
found a limited amount of gastrointestinal disturbance
and low blood counts as commonly observed adverse
events [61]. This study provides further impetus to test
Ezatiostat in future phase2 or 3 MDS studies, either as
monotherapy or in combination with lenalidomide.
Farnesyl Transferase Inhibitors (FTI)
Farnesyl transferases regulate post translational farne-
sylation of protein substrates that are involved in cell
signaling, proliferation and differentiation [62]. The
oncogenic Ras protein requires post translational
changes to become active in cancer cell lines with the
help of the enzyme Farnesyl Transferase. Gain of func-
tion mutations in RAS are commonly seen with various
cancers and this gene has been reported to be mutated
in about approximately 20% of MDS patients [63].
Hence inhibitors of Farnesylation, that have shown
antiangiogenic, antiproliferative and pro apoptotic
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in MDS.
Tipifarnib (R115777) was studied in a phase 1 setting by
Kurzrock et al. who tried doses of 300 mg BID for 8 weeks
schedule (3 weeks on and 1 week off). Of the 21 patients
treated, only 4 of them had RAS mutation. Authors
reported 30% objective response with 3 patients showing
HI, 2 showing PR and 1 reaching complete remission.
Interestingly, amongst the responders only 2 of these 6
patients had a RAS mutation. The maximal tolerable dose
as per this study was 400 mg BID and myelo-suppression
was a frequently reported side effect [67]. This was
followed by a multicenter phase 2 study reported in 2004,
where 28 patients received Tipifarnib. At doses of 600 mg
BID the compound was tested for 4 weeks followed by
2 weeks break. Treatment was discontinued at the end of
2 cycles if therapeutic effect was observed. A dose reduc-
tion to 300 mg BID was allowed for toxicities. Once res-
ponse was noted, patients were allowed to complete the
induction regime for a total of 12 months. Three res-
ponders were observed in the trial (Complete-2, Partial-1).
All responders had received an initial induction with
R115777 of 600 mg BID followed by dose reduction to
300 mg BID after 12 weeks. Low neutrophil count, weak-
ness, gastrointestinal upset were often reported adverse
events in the study [68]. A subsequent phase 2 study
reported in 2007 tested R115777 in int- high risk MDS. In
this study a total of 82 patients received the compound at
doses of 300 mg BID for 3 weeks followed by 1 week
break from the compound. Of the 26 responders 12 had
achieved CR, 14 had HI and about 45% (n-37) were noted
to be in stable disease. The median response duration
amongst patients who had achieved CR was about
11.5 months. Approximately 18% (neutropenia), (32%)
thrombocytopenia and (18%) anemia was reported
as drug related hematologic adverse events in this
study [69].
Lonafarnib is another farnesyl transferase inhibitor that
has been studied in MDS. In a phase 2 study, lonafarnib
was studied in MDS and CMML patients (N-67) [70]. The
drug was studied at doses of 200 mg BID and 300 mg BID.
For patients who had greater than Grade 2 toxicity the
dose was decreased to 150 mg BID after interruptions. In
this trial, HI was noted in 6 MDS patients and 10 CMML
patients. Diarrhea, fatigue and nausea were the commonly
reported adverse events with this compound. However
earlier treatment withdrawal was noted amongst pa-
tients in the trial and the authors recommended inter-
mittent dosing frequencies to be tested in future trials.
Another phase 2 trial reported a very small benefit of
lonafarnib in MDS at doses of 200 mg BID for 3
courses of 4 weeks separated by 1–4 weeks of drug
holiday [71]. With significant toxicity profile and mod-
est benefit, lonafarnib needs to be further tested inlarge population studies and varied dosing schedule to
find their clinical niche in MDS and AML.
Mek inhibitor
The binding of stimulatory growth factors can lead to the
activation of Ras, Raf, MEK and ERK signaling cascades.
These signaling cascades regulate proliferation, cell sur-
vival, angiogenesis and invasion [72]. Alteration in Mek/
Raf/Erk has been found to promote abnormal cell growth
in Kras mediated MDS/myeloproliferative neoplasm
(CMML/JMML) [73]. Constitutively activated MAP/Erk
kinase pathways in various cancers with activating mu-
tations in the RAS oncogene are often associated with
poor prognosis [74,75]. Blocking Mek pathways in
preclinical models of AML have resulted in growth
inhibitory effects [76] and could potentially sensitize
leukemic cells to chemotherapy induced apoptosis [77].
Mek kinase inhibitor, PD 0325901, has shown to im-
prove erythropoiesis and rectify abnormal proliferation
and differentiation pattern in mouse models of CMML
and JMML [78]. A more recent study reported in ASCO
2011 demonstrated utility of MEK inhibition in relapsed/
refractory myeloid neoplasm. GSK1120212 (Mek- inhibi-
tor) was given at 2 mg daily dose to 45 patients with K or
N RAS mutant MDS and led to an ORR of 31% and a
CR rate of 23%. Approximately 54% of these patients
exhibited stable disease [79]. The utility of MEK inhibitors
in suppressing mutant RAS mediated abnormal
myeloproliferation and its ability to suppress apoptosis is
currently being tested in clinical trials (Table 1).
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Etanercept
The efficacy of anti-TNF-α strategies in inflammatory
conditions like rheumatoid arthritis [80] encouraged the
testing of these agents in MDS. Increased levels of TNF-α
have been reported in MDS marrows and this cytokine
has been implicated in increased apoptosis noted with the
disease [81]. TNF α inhibition was first tested in
a phase 2 study by Deeg et al, in 12 MDS patients.
Patients enrolled in the study received Etanercept
25 mg s/c twice weekly dose with a plan to increase it
to three times a week if there was no improvement
in the counts by 8th week. The study showed
Hematologic Improvement in 3 parameters (erythroid =4,
neutrophils = 2, platelets = 2). Interestingly there was no
correlation observed between the pretreatment TNF-α
levels and hematologic response [82].Infliximab (Remicaide) (Chimeric TNF alpha antibody)
Similar to Etanercept, Remicade has also been used in
Rheumatoid arthritis (auto immune disorder) and tested
in MDS. Infliximab was tried in 2 cohorts of low risk
MDS with 5 and 10 mg/kg doses respectively. The drug
was designed to be given every 4 weeks for a total of 4 cy-
cles. A total of 28 patients completed 4 cycles of which 8
patients showed hematologic response while 6 patients
were found to have stable disease [83]. This was
followed by a randomized Phase-2 trial of Remicade in
low risk MDS patients (EORTC 06023). In this study,
the therapeutic efficacy of Infliximab at doses of 3 mg/k
and 5 mg/kg was evaluated. A low response rate was
noted with both the doses (3/22 versus 0/21 responses).
Hence the study authors concluded that TNF-α blockade
alone might be an insufficient therapeutic strategy in MDS.
Conclusion
Significant progress has been made in understanding the
role of various cytokine cascades in MDS. Difficulties in
stimulating normal marrow activity by conventional drugs
alone provide opportunity to explore newer compounds
that can alter and regulate ineffective hematopoiesis in
MDS marrows. Currently P38 MAPK inhibitors, mTOR
inhibitors, TGF-β pathway inhibitors, MEK inhibitors and
a few other compounds are being tested in various stages
of clinical development. Finding an appropriate combi-
nation of novel agents and dosing frequencies that will en-
hance hematologic recovery would remain a challenge
that needs to be addressed in newer studies. Future stu-
dies will be aided by correlative studies of Gene mutations,
aberrant DNA cytosine methylation and other genetic/
epi- genetic biomarkers that will help identify a subset of
MDS patients who might respond well to these new
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